HIV-1 p24抗原血症无法预测艾滋病患者的生存时间。
HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients.
作者信息
Mulder J W, Krijnen P, Goudsmit J, Schattenkerk J K, Reiss P, Lange J M
机构信息
Department of Internal Medicine, University of Amsterdam.
出版信息
Genitourin Med. 1990 Jun;66(3):138-41. doi: 10.1136/sti.66.3.138.
The time of survival in 176 AIDS patients was investigated in relation to the presence or absence of HIV-1 p24 antigenaemia at the moment of diagnosis. The median time of survival in p24 antigen positive patients was 12 months, in p24 antigen negative patients it was 13 months; no difference in survival curves was found. Also no difference was found in survival between patients with high and low p24 antigen levels. The median time of survival in patients for whom a diagnosis of AIDS was made in the period before the introduction of zidovudine treatment was 10 months; in patients diagnosed in the period thereafter it was 18 months (p less than 0.005). However, when each period was analysed separately, no difference in survival between p24 antigen positive and negative patients was found. Separate analysis of patients with a diagnosis of Kaposi's sarcoma alone showed similar results. HIV-1 p24 antigenaemia at the moment of diagnosis of AIDS (both in the period before and in the period after the introduction of zidovudine) is not a predictor for time of survival.
对176例艾滋病患者的生存时间进行了调查，研究其与诊断时是否存在HIV-1 p24抗原血症的关系。p24抗原阳性患者的中位生存时间为12个月，p24抗原阴性患者为13个月；未发现生存曲线有差异。p24抗原水平高和低的患者之间的生存情况也未发现差异。在齐多夫定治疗引入之前被诊断为艾滋病的患者，中位生存时间为10个月；在此之后被诊断的患者，中位生存时间为18个月（p<0.005）。然而，当分别分析每个时期时，p24抗原阳性和阴性患者之间的生存情况未发现差异。单独对仅诊断为卡波西肉瘤的患者进行分析，结果相似。艾滋病诊断时（在齐多夫定引入之前和之后的时期）的HIV-1 p24抗原血症不是生存时间的预测指标。
Zotero 插件